Immatics (IMTX)
Develops PRAME-focused cancer therapies with cell therapy and TCR bispecific programs.
Something off on this page? Send us feedback.
Develops PRAME-focused cancer immunotherapies through cell-therapy and TCR-bispecific programs. Its transatlantic organization operates in Germany and Houston, while the company remains clinical-stage with no products approved for commercial sale.
Develops PRAME-focused cancer immunotherapies using target-discovery and T-cell-receptor platforms. Clinical programs span cell therapies and TCR bispecifics, including anzu-cel in a Phase 3 trial for advanced melanoma.
Research and operations span Tübingen and Munich, Germany, and Houston, Texas, reflecting a transatlantic model. Founded as a University of Tübingen spinout, the U.S. presence grew from a joint venture with MD Anderson Cancer Center.
Co-founder Harpreet Singh remains chief executive. These programs rely on clinical development, while strategic-collaboration revenue comes from Moderna and BMS. The company has no products approved for commercial sale.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 25, 2026 | Jefferies | Target | Target: — | Target: $17 |
| Feb 19, 2026 | Mizuho Securities | Target | Target: $19 | Target: $25 |
| Dec 4, 2025 | Leerink Partners | Target | Target: — | Target: $17 |
| Oct 29, 2025 | Mizuho Securities | Target | Target: $16 | Target: $19 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $449.6M · Total debt $16.7M · Total assets $555.2M · Shareholders' equity $456.8M
- Revenue
- $10.5M
- Operating income
- −$76.8M
- Net income
- −$71.5M
Reported in EUR, converted at the latest exchange rate
No dividends on record.
| Institutions | 74.44% | 99.80M ADS | |
|---|---|---|---|
| 85 holders · as of Jun 30, 2026 | |||
| Insiders | 0.54% | 718.6K ADS | |
| 7 holders · as of Mar 18, 2026 | |||
| Other | 25.02% | 33.55M ADS | |
| remainder | |||
134.07M ADS as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
T. Rowe Price Investment Management, Inc.Institution | 16.68% | 22.37M ADS | as of Jun 30, 2026 |
RTW Investments, LPInstitution | 9.66% | 12.95M ADS | as of Jun 30, 2026 |
Suvretta Capital Management, LLCInstitution | 8.35% | 11.19M ADS | as of Jun 30, 2026 |
Perceptive Advisors LLCInstitution | 7.74% | 10.38M ADS | as of Jun 30, 2026 |
Baker Bros. Advisors LPInstitution | 7.09% | 9.51M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 26, 2026 | Perceptive Advisors LLC | director | +863,060 | $8.69 |
- Immunocore (ADR)
PRAME bispecifics and advanced-melanoma T-cell therapy
- Iovance Biotherapeutics
Individualized cell therapy for advanced melanoma
- TScan Therapeutics
PRAME and MAGE-A4 engineered TCR-T programs for solid tumors
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Immatics | $8.79 | +0.80% | $1.17B | — | — | 24.5 | +113.0% |
| Immunocore (ADR) | $32.24 | +0.20% | $1.64B | — | — | 4.1 | −13.7% |
| Iovance Biotherapeutics | $10.32 | +1.28% | $4.55B | — | — | 14.0 | +65.7% |
| TScan Therapeutics | $0.3503 | +5.96% | $20.2M | — | — | 2.8 | −65.8% |
| Median | — | — | 4.1 | −13.7% |